Cellular tumor antigen p53
Cellular tumor antigen p53 (217-225) is a synthetic peptide fragment corresponding to amino acids 217 through 225 of the human p53 protein, a key tumor suppressor involved in cell cycle regulation, DNA repair, and apoptosis. As a well-defined epitope within the p53 sequence, this peptide is widely utilized in molecular biology and immunological research to explore the functional dynamics of p53, its interactions with other biomolecules, and its role in oncogenic processes. The sequence's relevance to immune recognition and antigen presentation makes it an essential tool for studies focused on cancer biology, T cell responses, and peptide-MHC binding mechanisms.
Epitope mapping: Researchers frequently employ the 217-225 peptide to map immunodominant epitopes within the p53 protein, facilitating the identification of specific regions recognized by T cells or antibodies. By using this defined peptide fragment in assays such as ELISPOT, flow cytometry, or peptide-MHC tetramer staining, investigators can delineate the immune response specificity toward p53, which is particularly valuable in tumor immunology and autoimmunity studies.
T cell activation assays: The 217-225 region of p53 is known to be presented by certain HLA molecules, making it a valuable reagent for in vitro stimulation of antigen-specific cytotoxic T lymphocytes (CTLs). Incorporation of this peptide into cellular assays enables the functional assessment of T cell recognition, cytokine secretion, and cytolytic activity, supporting the development and validation of immunotherapeutic strategies that target p53-expressing tumor cells.
Peptide-MHC binding studies: As a defined MHC class I-restricted epitope, the 217-225 peptide serves as a model substrate for quantitative and qualitative analyses of peptide binding to HLA molecules. These studies are fundamental for understanding antigen processing, peptide affinity, and the structural determinants of immune recognition, thereby informing rational design of peptide-based immunotherapies and vaccines.
Antibody specificity assays: The peptide is also utilized in the evaluation of monoclonal and polyclonal antibody specificity against p53. By incorporating it into ELISA, western blot, or surface plasmon resonance experiments, researchers can assess the binding characteristics of anti-p53 antibodies, differentiate between linear and conformational epitopes, and validate reagents for diagnostic or research applications.
Peptide synthesis and modification research: Beyond its direct applications in immunology, the 217-225 fragment of p53 is frequently used as a model system in peptide chemistry. Its sequence is suitable for investigations into peptide synthesis methodologies, post-translational modification studies, and structure-activity relationship analyses, enabling optimization of synthetic protocols and exploration of peptide stability, folding, and functionalization within a biologically relevant context.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More